Interactions and potential risks of odevixibat with other drugs

Odevixibat (Odevixibat) is an oral selective intestinal bile acid transporter inhibitor (IBAT inhibitor). It is mainly used to treat chronic cholestatic liver diseases in children (such as PFIC). It inhibits intestinal bile acid reabsorption and reduces serum bile acid levels, thereby improving itching and abnormal liver function. In clinical applications, it is important to understand the interactions and potential risks of odexibat with other drugs to ensure the safety and efficacy of treatment.

Odesibat may affect the absorption of oral medications . Because it acts on the intestinal bile acid cycle, it will change the intestinal environment and the absorption of fat-soluble substances. For fat-soluble vitamins that rely on bile acid-mediated absorption (such as vitamins A, D span>, E, K) and some oral drugs (such as cyclosporine, some immunosuppressants) may affect bioavailability. Therefore, when taking drugs together, the blood concentrations of relevant drugs or nutrients should be monitored, and the dosage should be adjusted or nutrition supplemented if necessary.

Odesibat does not significantly inhibit or induce major CYP enzyme systems in the body, so there is a low risk of interaction with most drugs metabolized by the liver (such as anti-epileptic drugs, some antibiotics, or antiviral drugs). However, patients who take multiple drugs in combination for a long period of time still need to be alert to potential changes in intestinal absorption, excretion, or systemic exposure levels of the drugs, especially in pediatric patients, who may be more sensitive to fluctuations in drug concentrations and bile acid levels.

Odesibat may cause fat-soluble vitamin deficiencies and coagulation abnormalities, especially with long-term use. Patients who use anticoagulants in combination or have bleeding tendencies need to closely monitor their coagulation function and vitamin K levels to prevent an increased risk of bleeding. At the same time, for patients who use other liver-acting drugs in combination, they should pay attention to changes in liver function and adjust the treatment plan in a timely manner.

Overall, changes in intestinal absorption and deficiencies in fat-soluble nutrients are of major concern with odexibat when used in combination with other drugs, with a low risk of CYP-mediated drug interactions. Clinically, blood drug concentration, liver function, vitamin levels and coagulation indicators should be regularly monitored based on the patient's specific medication use and disease characteristics to minimize potential risks and ensure a balance between efficacy and safety.

Reference link:https://www.drugs.com